Patients with systemic sclerosis complicated by both pulmonary hypertension (SSc‐PH) and
interstitial lung disease (SSc‐PH‐ILD) have poor prognosis compared to those with SSc‐PH …

Objectives The prevalence and characteristics of SSc-associated interstitial lung disease
(SSc-ILD) vary between geographical regions worldwide. The objectives of this study were …

Objective To quantify the burden of interstitial lung disease (ILD) in SSc. Methods Clinical
data for SSc patients enrolled in the Australian Scleroderma Cohort Study were linked with …

Objectives Interstitial lung disease (ILD) in CTDs has highly variable morphology. We aimed
to identify imaging features and their impact on ILD progression, mortality, and …

Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of
mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the …

Objective To determine the prognostic value of pulmonary function test (PFT) trends at 1 and
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …

Purpose. Interstitial lung disease (ILD) related to systemic sclerosis (SSc) is assessed with
pulmonary functional tests (PFTs) and semi-quantitative scores based on extent of ILD …

Introduction: Systemic sclerosis–associated interstitial lung disease accounts for up to 20%
of mortality in these patients and has a highly variable prognosis. Functional respiratory …

Some of the most pressing challenges associated with interstitial lung disease (ILD) are how
best to define, diagnose, and treat connective tissue disease-associated ILD (CTD-ILD) …